Liu Huan, Yu Cheng, Lyu Min, Lyu Shiyi, Hu LiNan, Xiao Enhua, Xu Pengfei
Departments of Radiology, The Second Xiangya Hospital, Central South University Changsha 410011 Hunan P. R. China
Departments of Radiology, Zhuzhou Central Hospital Zhuzhou 412000 Hunan P. R. China.
RSC Adv. 2023 Jan 25;13(6):3534-3540. doi: 10.1039/d2ra07380c. eCollection 2023 Jan 24.
The targeted and novel albumin-binding strategy has been attractive in the field of cancer therapy. Herein, we have developed an organic small molecule-based photosensitizer, Evans Blue-Pyropheophorbide-alpha (EB-Ppa), to treat solid tumors with extremely high photodynamic therapeutic efficiency, which is stable in serum-containing aqueous media and can effectively accumulate in the tumor site due to the enhanced permeability and retention (EPR) effect. Particularly, after the photodynamic therapeutic treatment with EB-Ppa, all breast tumors (4T1 cell line) xenografted in nude mice shrink fast due to the singlet oxygen generated by EB-Ppa with laser irradiation. Furthermore, EB-Ppa shows negligible toxicity in major organs. These results demonstrate that EB-Ppa presents the great potential of photodynamic therapy for efficient tumor treatment.
靶向性新型白蛋白结合策略在癌症治疗领域颇具吸引力。在此，我们研发了一种基于有机小分子的光敏剂，伊文思蓝-焦脱镁叶绿酸-α（EB-Ppa），用于以极高的光动力治疗效率治疗实体瘤，其在含血清的水性介质中稳定，且由于增强的渗透和滞留（EPR）效应可有效积聚于肿瘤部位。特别地，在用EB-Ppa进行光动力治疗后，裸鼠体内移植的所有乳腺肿瘤（4T1细胞系）因EB-Ppa在激光照射下产生的单线态氧而迅速缩小。此外，EB-Ppa在主要器官中显示出可忽略不计的毒性。这些结果表明，EB-Ppa在高效肿瘤治疗的光动力疗法方面具有巨大潜力。
